Newcross celebrates and supports government roll-out of COVID-19 vaccines - Cloned
We're delighted at the news that the Pfizer/BioNTech COVID-19 vaccine has been judged safe for use in UK from next week with the AstraZeneca vaccine likely to follow soon. We praise the rapid development of these vaccines and wholeheartedly support the roll-out of any and all vaccines approved by the UK government.
This fantastic news follows months of rigorous clinical trials and a thorough analysis of the data by experts at the British Medicines and Healthcare products Regulatory Agency (BMHRA) who have concluded that the Pfizer/BioNTech vaccine has met its standards of safety, quality and effectiveness.
Analysis shows the vaccine can prevent 95% of people from getting the virus, including 94% in older age groups.
The development of a coronavirus vaccine has been fast-tracked because of the dire need to protect most vulnerable and the world at large from the impact of this illness. The rapid turnaround time is an enormous feat of ingenuity and due to the financial backing of governments around the world. All vaccines approved by the BMHRA are rigorously trialed and tested for widespread use. We wholeheartedly trust in their efficacy and safety.
As soon as I am eligible, I will book a slot to access my vaccine. All Newcross staff will be encouraged to also do their bit to put an end to the pandemic and protect themselves, their loved ones and clients.
- Michelle Gorringe, COO and Co-founder of Newcross Healthcare
How does the Pfizer/BioNTech vaccine work?
This jab is known as a messenger RNA (mRNA) vaccine. Typically, vaccines are produced using weakened forms of the virus. However, mRNA vaccines use a version of the virus' genetic code, and no virus cells are required. When administered, it enters cells and tells them to create antigens. These antigens are in turn recognised by the immune system and prepare it to fight coronavirus.
For more information on the science behind this vaccine, you can read this article produced by Pfizer.
We look forward to roll out of the Pfizer/BioNTech vaccine, and alternative versions, once they are approved for use in the UK.